Clinical Trial Update: Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating oral mitoquinone/mitoquinol mesylate as postexposure prophylaxis for COVID-19 is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars Coronavirus Infection

Drugs mentioned

• Mitoquinol Mesylate (mitoquinol mesylate)
• Mitoquinone (mitoquinone)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: SARS-CoV Infection, COVID-19 | Phase 2 | Status: RECRUITING